sarpogrelate has been researched along with Peripheral Arterial Diseases in 7 studies
sarpogrelate: structure given in first source
Excerpt | Relevance | Reference |
---|---|---|
"Sarpogrelate was effective for improving the symptoms of PAD and showed good tolerability without significant adverse events." | 6.61 | Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials. ( Li, J; Liao, L; Lu, Y; Xie, J; Yu, Q, 2019) |
"Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine 2A antagonist, is a widely used antiplatelet agent for the treatment of peripheral arterial disease (PAD)." | 5.22 | Efficacy and Safety of DP-R202 in Patients with Chronic Artery Occlusive Disease: Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Clinical Study. ( Ahn, YK; Chae, IH; Chang, KY; Cho, BR; Cho, DK; Choi, D; Choi, S; Chun, K; Han, KR; Hong, BK; Jin, HY; Kang, W; Kim, DI; Kim, DW; Kim, SH; Kim, YJ; Lee, HC; Lee, JW; Lee, NH; Lee, S; Lee, SR; Park, CG; Pyun, W; Shin, JH; Yu, CW, 2016) |
"The effect of the prostaglandin I2 analog, beraprost sodium (BPS), on hemodialysis (HD) patients with peripheral arterial disease (PAD) has not been fully elucidated." | 5.19 | Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. ( Hidaka, S; Kobayashi, S; Kondoh, M; Miyaji, T; Moriya, H; Nakazawa, R; Ohtake, T; Sato, M, 2014) |
" Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months." | 2.84 | SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. ( Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017) |
"Sarpogrelate was effective for improving the symptoms of PAD and showed good tolerability without significant adverse events." | 2.61 | Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials. ( Li, J; Liao, L; Lu, Y; Xie, J; Yu, Q, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (85.71) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Han, A | 1 |
Lee, T | 1 |
Lee, J | 2 |
Song, SW | 1 |
Lee, SS | 1 |
Jung, IM | 1 |
Kang, JM | 1 |
Gwon, JG | 1 |
Yun, WS | 1 |
Cho, YP | 1 |
Ko, H | 1 |
Park, YJ | 1 |
Min, SK | 2 |
Lu, Y | 1 |
Li, J | 1 |
Xie, J | 1 |
Yu, Q | 1 |
Liao, L | 1 |
Ahn, S | 1 |
Ha, J | 1 |
Min, SI | 1 |
Kim, SY | 1 |
Cho, MJ | 1 |
Cho, S | 1 |
Ohtake, T | 2 |
Sato, M | 1 |
Nakazawa, R | 1 |
Kondoh, M | 1 |
Miyaji, T | 1 |
Moriya, H | 2 |
Hidaka, S | 2 |
Kobayashi, S | 2 |
Lee, HC | 1 |
Lee, SR | 1 |
Han, KR | 1 |
Yu, CW | 1 |
Park, CG | 1 |
Ahn, YK | 1 |
Jin, HY | 1 |
Kim, DW | 1 |
Cho, DK | 1 |
Choi, S | 1 |
Kim, SH | 1 |
Chang, KY | 1 |
Lee, S | 1 |
Pyun, W | 1 |
Lee, NH | 1 |
Kang, W | 1 |
Hong, BK | 1 |
Cho, BR | 1 |
Chae, IH | 1 |
Shin, JH | 1 |
Chun, K | 1 |
Kim, DI | 1 |
Lee, JW | 1 |
Kim, YJ | 1 |
Choi, D | 1 |
Soga, Y | 1 |
Shintani, Y | 1 |
Hamasaki, T | 1 |
Tomoi, Y | 1 |
Takaoka, J | 1 |
Suematsu, N | 1 |
Yokoi, H | 1 |
Ando, K | 1 |
Iwagami, M | 1 |
Isshiki, R | 1 |
Tsutsumi, D | 1 |
Mochida, Y | 1 |
Ishioka, K | 1 |
Oka, M | 1 |
Maesato, K | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial[NCT02959606] | Phase 4 | 272 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for sarpogrelate and Peripheral Arterial Diseases
Article | Year |
---|---|
Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Ankle Brachial Index; Female; Humans; Male; Middle Aged; Peripheral Arterial Disease; P | 2019 |
6 trials available for sarpogrelate and Peripheral Arterial Diseases
Article | Year |
---|---|
A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention.
Topics: Aspirin; Clopidogrel; Delayed-Action Preparations; Drug Therapy, Combination; Femoral Artery; Humans | 2023 |
SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.
Topics: Amputation, Surgical; Aspirin; Clinical Protocols; Clopidogrel; Computed Tomography Angiography; Con | 2017 |
Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients.
Topics: Aged; Aged, 80 and over; Cilostazol; Epoprostenol; Female; Heart Rate; Humans; Male; Microcirculatio | 2014 |
Efficacy and Safety of DP-R202 in Patients with Chronic Artery Occlusive Disease: Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Clinical Study.
Topics: Aged; Arteries; Double-Blind Method; Female; Humans; Male; Middle Aged; Pain; Pain Measurement; Peri | 2016 |
Effectiveness of sarpogrelate after endovascular treatment for femoropopliteal artery disease: ESPALIER study.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Endovascular Procedures; Female; Femoral Artery; Huma | 2017 |
Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease.
Topics: Aged; Blood Pressure; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Lower Extremity; M | 2013 |